PPARalpha: an emerging therapeutic target in diabetic microvascular damage

Area of Science:

• Endocrinology
• Diabetology
• Vascular Biology

Background:

• Diabetes mellitus causes widespread microvascular complications affecting the retina, kidneys, and nerves.
• Peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in key organs affected by diabetic microvascular disease.
• PPARalpha activation may counteract vascular damage mediators like lipotoxicity, inflammation, and oxidative stress.

Purpose of the Study:

• To review the role of PPARalpha activation in diabetic microvascular disease.
• To analyze experimental and clinical evidence of PPARalpha agonists in preventing vascular damage.

Main Methods:

• Review of experimental studies on PPARalpha activation in diabetic models.
• Analysis of clinical trial data, including the FIELD study, on PPARalpha agonists in diabetic patients.

Main Results:

• Experimental data strongly support PPARalpha activation's potential to prevent vascular damage through lipid-related and unrelated mechanisms.
• Clinical evidence remains limited; the FIELD study showed some microvascular benefits but also increased homocysteine and creatinine levels.

Conclusions:

• PPARalpha is a potential therapeutic target for diabetic microvascular complications.
• Further clinical studies are needed to fully evaluate the efficacy and safety of PPARalpha agonists in diabetic patients.